Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes... Show more
IMDX saw its Momentum Indicator move above the 0 level on September 09, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at .
IMDX moved above its 50-day moving average on September 10, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IMDX crossed bullishly above the 50-day moving average on September 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMDX advanced for three days, in of 199 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for IMDX moved out of overbought territory on September 22, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 45 cases where IMDX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The 50-day moving average for IMDX moved below the 200-day moving average on September 04, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IMDX broke above its upper Bollinger Band on September 16, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMDX entered a downward trend on August 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: IMDX's P/B Ratio (84.746) is very high in comparison to the industry average of (9.327). P/E Ratio (0.000) is within average values for comparable stocks, (133.211). IMDX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.640). Dividend Yield (0.000) settles around the average of (0.023) among similar stocks. P/S Ratio (17.007) is also within normal values, averaging (9.059).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a developer of ovel, non-invasive, liquid biopsy diagnostics for the early detection of cancer
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, IMDX has been loosely correlated with NEPH. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if IMDX jumps, then NEPH could also see price increases.
Ticker / NAME | Correlation To IMDX | 1D Price Change % | ||
---|---|---|---|---|
IMDX | 100% | -0.46% | ||
NEPH - IMDX | 34% Loosely correlated | +0.72% | ||
FONR - IMDX | 31% Poorly correlated | -0.13% | ||
MASS - IMDX | 24% Poorly correlated | +8.73% | ||
MLSS - IMDX | 24% Poorly correlated | -0.97% | ||
VNRX - IMDX | 23% Poorly correlated | -0.88% | ||
More |